Hence, combining anti-VEGF and anti-VEGFC appears to be relevant for the treatment of triple negative breast cancers for which VEGFC/VEGFR3/NRP1 signaling is detrimental [10]. Here, NRP1 is linked to triple-negative breast carcinoma.